Pacific Biosciences of California, a maker of DNA sequencing equipment that has seen its stock rise dramatically in recent years, said Tuesday that it will purchase Omniome, a smaller rival, for up to $800 million.
PacBio, as the firm is known, will offer $600 million, half in cash and half in stock, up front. It will pay another $200 million when and if machines based on Omniome’s technology first ship to customers. In order to finance the deal, PacBio is selling $300 million in a private placement to existing investors.
The company also announced that it and its partner Invitae, a diagnostics company, intend to expand their collaboration to include Omniome’s technology.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
